Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting - Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment (Detail)

v3.7.0.1
Segment Reporting - Summary of Net Revenue Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment (Detail) - USD ($)
 3 Months Ended
Feb. 28, 2017
Feb. 29, 2016
Nov. 30, 2016
Segment Reporting Information [Line Items]      
Total net revenue $ 5,776,624 $ 5,152,198  
Total cost of sales 1,516,097 1,348,291  
Total depreciation and amortization 31,630 41,548  
Total operating income 1,116,126 156,422  
Total interest expense 297,044 261,334  
Total income tax benefit (expense) (305,717) 0  
Total other comprehensive income (7,061) (93,727)  
Total assets 19,753,355 19,538,468 $ 19,538,468
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]      
Segment Reporting Information [Line Items]      
Total net revenue 5,611,824 5,020,459  
Total cost of sales 1,392,795 1,245,023  
Total depreciation and amortization 22,566 28,678  
Total operating income 1,083,692 127,951  
Total interest expense 297,044 246,943  
Total income tax benefit (expense) (305,717)    
Total other comprehensive income (7,061) (93,727)  
Total assets 19,186,558 18,960,261  
PrepaCyte CB [Member]      
Segment Reporting Information [Line Items]      
Total net revenue 164,800 131,739  
Total cost of sales 123,302 103,268  
Total depreciation and amortization 9,064 12,870  
Total operating income 32,434 28,471  
Total interest expense   14,391  
Total assets $ 566,797 $ 578,207